Video Experimental Relacionado
Updated: Feb 9, 2026
04:38
Assessment of Sexual Behavior of Male Mice
Published on: March 5, 2020
21.9K
Agonistas de los receptores GLP-1 de acción corta y prolongada disminuyen los comportamientos sexuales femeninos en
Olesya Shevchouk1, Christian E Edvardsson1, Mia Ericson2
1Institute of Neuroscience and Physiology, Department of Pharmacology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Behavioural brain research
|February 7, 2026
Resumen
Los agonistas del receptor del péptido similar al glucagón tipo 1 (GLP-1R) impactan los comportamientos sexuales y sociales femeninos, con efectos que varían según el fármaco y la especie. Estos hallazgos revelan impactos específicos de la especie y del agonista en las funciones de recompensa femeninas.
Área de la Ciencia:
- Neurociencia; Endocrinología; Ciencia Conductual
Sus antecedentes:
- Los agonistas del receptor del péptido similar al glucagón tipo 1 (GLP-1R) influyen en las vías metabólicas y de recompensa.; Estudios previos muestran que los agonistas del GLP-1R de acción corta afectan el comportamiento sexual masculino, pero se desconocen las respuestas femeninas.
Objetivo del estudio:
- Investigar los efectos de los agonistas del GLP-1R de acción prolongada (dulaglutida, liraglutida) y de acción corta (exendina-4) sobre los comportamientos sexuales y sociales en ratas y ratones hembras.; Explorar los posibles mecanismos neuroquímicos subyacentes a estos cambios conductuales.
Principales métodos:
- Administración de agonistas del GLP-1R (dulaglutida, liraglutida, exendina-4) a ratas y ratones hembras sexualmente experimentados.; Evaluación de comportamientos sexuales (p. ej., montas, intromisiones, lordosis) y comportamientos sociales (p. ej., novedad social, sociabilidad) utilizando paradigmas conductuales establecidos.; Análisis de cambios neuroquímicos en el núcleo del tracto solitario (NTS) y el septo lateral (LS).
Principales resultados:
- Los agonistas del GLP-1R disminuyeron los comportamientos sexuales en ratas y ratones hembras, con notables diferencias específicas del fármaco y de la especie.; La liraglutida y la dulaglutida redujeron la novedad social y aumentaron la sociabilidad en ratones hembras.; Las alteraciones neuroquímicas incluyeron un aumento de la noradrenalina en el NTS y cambios en el glutamato, la glutamina y la taurina en el LS.
Conclusiones:
- La activación del GLP-1R ejerce efectos específicos de la especie y del agonista sobre los comportamientos sexuales y sociales femeninos.; Estos hallazgos amplían la comprensión del papel del GLP-1 en la modulación de los comportamientos relacionados con la recompensa más allá de las funciones metabólicas.
Videos de Conceptos Relacionados
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.9K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.9K
01:24Glucagon-like Receptor Agonists
990
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
990
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.8K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.8K
01:22Indirect-Acting Cholinergic Agonists: Pharmacokinetics
1.6K
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.6K
01:30Adrenergic Agonists: Direct-Acting Agents
2.8K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
2.8K
01:25Adrenergic Agonists: Indirect-Acting Agents
2.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.8K